Successfully targeting the cancer system with metronomics for medulloblastoma.
angiogenesis
cancer
cancer system
children
drug repurposing
immune system
medulloblastoma
metronomic chemotherapy
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
10
10
2023
revised:
17
10
2023
accepted:
20
10
2023
medline:
27
11
2023
pubmed:
9
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
The prognosis of the patients with medulloblastoma who relapse after initial treatment including radiotherapy remains dismal. A recent study by Peyrl et al. in JAMA Oncology suggests that the metronomic multidrug combination used in the medulloblastoma European multitarget metronomic antiangiogenic trial (MEMMAT) given at relapse can improve long-term survival.
Identifiants
pubmed: 37940401
pii: S2405-8033(23)00215-7
doi: 10.1016/j.trecan.2023.10.004
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
989-991Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests N.A. has had an advisory role at BAYER, Partner Therapeutics, and Alexion, and receives grants (institution) from Bristol Myers Squibb and drugs for a trial from Bristol Myers Squibb, Pierre Fabre, and Pfizer, and travel support from Roche; he also has Independent Data Safety Monitoring Committee (IDMC) roles for Accord Healthcare. The other authors declare no conflicts of interest.